Breast cancer resistance protein (BCRP/MXR/ABCG2) in adult acute lymphoblastic leukaemia: frequent expression and possible correlation with shorter disease‐free survival

Attaya Suvannasankha(Indiana University Health), Maria R. Baer(University of Maryland, Baltimore), Meir Wetzler, Takeo Nakanishi(Takasaki University of Health and Welfare), Douglas D. Ross(Western University), William R. Greco(Roswell Park Comprehensive Cancer Center), Kieran L. O’Loughlin(Roswell Park Comprehensive Cancer Center), Laurie Ford(Roswell Park Comprehensive Cancer Center), Hans Minderman(Roswell Park Comprehensive Cancer Center)
British Journal of Haematology
November 1, 2004
10.1111/j.1365-2141.2004.05211.x
Cited by 63

Related Papers

Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
<i>IDH1</i> and <i>IDH2</i> Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
|Journal of Clinical Oncology|2010|764
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study
|The Lancet Oncology|2017|493
Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia
|Journal of Clinical Oncology|2012|408